You are here

  • Home
  • Archive
  • Volume 6, Issue 1
  • STAT3 antisense oligonucleotide AZD9150 in a subset of patients with heavily pretreated lymphoma: results of a phase 1b trial

Article metrics

Article menu

Download PDFPDF

Research Article
STAT3 antisense oligonucleotide AZD9150 in a subset of patients with heavily pretreated lymphoma: results of a phase 1b trial

 

Online download statistics by month:

Online download statistics by month: December 2019 to March 2024

AbstractFullPdf
Dec 2019110
Jan 202017170
Feb 2020323213
Mar 2020565616
Apr 202031313
May 202056564
Jun 2020373714
Jul 2020343413
Aug 2020232311
Sep 2020515111
Oct 2020707018
Nov 2020494914
Dec 2020494917
Jan 2021686831
Feb 2021434331
Mar 2021717144
Apr 2021545443
May 2021545430
Jun 2021626229
Jul 2021555521
Aug 2021373715
Sep 2021414222
Oct 2021585845
Nov 2021626234
Dec 2021494917
Jan 202212513561
Feb 20229310028
Mar 2022818725
Apr 2022657643
May 2022636434
Jun 2022596424
Jul 2022556321
Aug 2022889226
Sep 2022505019
Oct 2022707419
Nov 2022798134
Dec 2022777813
Jan 2023636417
Feb 202312012222
Mar 2023989932
Apr 2023676922
May 2023505223
Jun 2023485015
Jul 2023565726
Aug 2023596023
Sep 2023888816
Oct 202317717713
Nov 202341941925
Dec 202325225413
Jan 2024585958
Feb 2024676816
Mar 202410510688
Total379238691252